Ekso Bionics Holdings, Inc.

As of March 31, 2026, Ekso Bionics Holdings, Inc. has 3.56M shares outstanding.

These figures are as of March 31, 2026. The price-to-sales ratio is 2.57, and the price-to-book ratio stands at -0.11.

These figures are as of March 31, 2026. The EV/Sales ratio of 2.91 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative.

As of March 31, 2026, Ekso Bionics Holdings, Inc. maintains a current ratio of 1.55, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 75.21, indicating elevated leverage, while an interest coverage ratio of -36.36 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended March 31, 2026. Return on assets (ROA) is negative at -66.79, reflecting losses generated across the asset base. Inventory turnover of 1.13 indicates how many times Ekso Bionics Holdings, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, Ekso Bionics Holdings, Inc. posted a gross margin of 52.86, reflecting its pricing power and cost economics. The operating margin of -134.06 and net profit margin of -135.66 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield is negative at -39.70: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -27.13, meaning Ekso Bionics Holdings, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Ekso Bionics Holdings, Inc.'s most recent stock split took place on June 2, 2025 with a 15:1 split ratio.

As of March 31, 2026, Ekso Bionics Holdings, Inc. has an Altman Z-Score of -24.68, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.